ClinicalTrials.gg
CompletedNCT00464945Updated Aug 15, 2012Results posted

Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccines, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Poland. Open to participants aged 41 Days to 99 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
41 Days to 99 Days
Sex
All
01

Study summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate (13vPnC) vaccine compared to pilot scale 13vPnC in healthy infants when given with routine pediatric vaccines.

02

Conditions studied

  • Pneumococcal Vaccines
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
41 Days to 99 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 2 months (42 to 98 days) at time of enrollment.
  2. Available for entire study period and whose parent/legal guardian can be reached by telephone.
  3. Healthy infant as determined by medical history, physical examination, and judgment of the investigator.
  4. Parent/legal guardian must be able to complete all relevant study procedures during study participation.

Exclusion criteria

Exclusion criteria:

  1. Previous vaccination with licensed or pneumococcal, Hib conjugate, diphtheria, tetanus, pertussis, or polio vaccines.
  2. A previous anaphylactic reaction to any vaccine or vaccine-related component.
  3. to vaccination with Hib conjugate, diphtheria, tetanus, pertussis, polio, , measles, mumps, rubella, or pneumococcal vaccines.
  4. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection.
  5. Known or suspected immune deficiency or suppression.
  6. History of culture-proven invasive disease caused by S pneumoniae.
  7. Major known congenital malformation or serious chronic disorders.
  8. Significant neurological disorder or history of seizure including febrile seizure, or significant stable or evolving disorders such as cerebral palsy, encephalopathy, hydrocephalus, or other significant disorders. Does not include resolving syndromes due to birth trauma such as Erb palsy.
  9. Receipt of blood products or gamma-globulin (including hepatitis B immunoglobulin and monoclonal antibodies; eg, Synagis®).
  10. Participation in another investigational or interventional trial. Participation in purely observational studies is acceptable.
  11. Infant who is a direct descendant (child or grandchild) of a member of the study site personnel.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    2

    Biological: 13-valent Pneumococcal Conjugate Vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series

    Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after 3-dose infant series (5 months of age)

  2. Percentage of Participants Reporting Pre-Specified Local Reactions

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  3. Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)

    Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after each dose

  4. Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)

    Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: During the 4-day period after toddler dose

  5. Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series

    Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: One month after 3-dose infant series (5 months of age)

07

Results

Posted Aug 15, 2012

Participant flow

Participants were recruited in Poland from June 2007 to August 2007.

Infant Series
Participant flow — Infant Series
Milestone13vPnC Manufacturing13vPnC Pilot
Started135134
Vaccinated dose 1134134
Vaccinated dose 2132133
Vaccinated dose 3132133
Completed131133
Not completed41
Withdrew: Withdrawal by parent/guardian request21
Withdrew: Protocol violation10
Withdrew: Lost to follow-up10
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC Manufacturing13vPnC Pilot
Started131133
Completed131131
Not completed02
Withdrew: Withdrawal by subject02
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC Manufacturing13vPnC Pilot
Started131131
Completed131130
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series

Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series
percentage of participants13vPnC Manufacturing13vPnC Pilot
Common Serotypes-Serotype 497.7 (93.3 to 99.5)96.9 (92.4 to 99.2)
Common Serotypes-Serotype 6B77.3 (69.1 to 84.3)74.0 (65.7 to 81.3)
Common Serotypes-Serotype 9V98.4 (94.5 to 99.8)96.2 (91.3 to 98.7)
Common Serotypes-Serotype 1492.9 (87.0 to 96.7)94.5 (89.1 to 97.8)
Common Serotypes-Serotype 18C96.1 (91.1 to 98.7)93.1 (87.4 to 96.8)
Common Serotypes-Serotype 19F98.4 (94.4 to 99.8)97.7 (93.5 to 99.5)
Common Serotypes-Serotype 23F82.8 (75.1 to 88.9)81.7 (74.0 to 87.9)
Additional Serotypes-Serotype 193.0 (87.1 to 96.7)90.8 (84.5 to 95.2)
Additional Serotypes-Serotype 393.7 (88.0 to 97.2)95.4 (90.3 to 98.3)
Additional Serotypes-Serotype 590.6 (84.2 to 95.1)88.5 (81.8 to 93.4)
Additional Serotypes-Serotype 6A85.2 (77.8 to 90.8)86.3 (79.2 to 91.6)
Additional Serotypes-Serotype 7F100.0 (97.2 to 100.0)100.0 (97.2 to 100.0)
Additional Serotypes-Serotype 19A99.2 (95.7 to 100.0)99.2 (95.8 to 100.0)
Statistical analysis
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 0.7 · 95% CI -3.9 to 5.6
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 3.3 · 95% CI -7.3 to 13.8
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 2.3 · 95% CI -2.1 to 7.3
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: -1.6 · 95% CI -8.2 to 4.7
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 3.0 · 95% CI -2.8 to 9.2
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 0.7 · 95% CI -3.5 to 5.1
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 1.1 · 95% CI -8.4 to 10.6
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 2.1 · 95% CI -4.8 to 9.2
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: -1.7 · 95% CI -7.9 to 4.2
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 2.1 · 95% CI -5.6 to 9.9
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: -1.1 · 95% CI -9.9 to 7.6
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: 0.0 · 95% CI -3.0 to 2.8
  • 13vPnC Manufacturing vs 13vPnC Pilot · Difference: -0.0 · 95% CI -3.6 to 3.5
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions
percentage of participants13vPnC Manufacturing Dose 113vPnC Pilot Dose 113vPnC Manufacturing Dose 213vPnC Pilot Dose 213vPnC Manufacturing Dose 313vPnC Pilot Dose 313vPnC Manufacturing Toddler Dose13vPnC Pilot Toddler Dose
Tenderness-Any (n=133,130,128,128,124,119,115,117)18.820.020.317.215.312.624.329.1
Tenderness-Sig (n=131,129,128,128,124,119,112,114)0.83.91.63.11.60.01.83.5
Swelling-Any (n=132,130,129,129,126,122,113,115)25.020.030.227.129.430.322.126.1
Swelling-Mild (n=132,130,129,129,126,121,113,115)22.717.729.525.627.025.622.125.2
Swelling-Mod (n=132,129,128,128,124,120,113,114)6.17.08.68.68.913.38.88.8
Swelling-Severe(n=131,129,128,128,124,119,112,113)0.00.00.00.00.00.00.00.0
Redness-Any (n=132,131,129,131,125,123,115,116)28.824.437.233.640.034.137.442.2
Redness-Mild (n=132,131,129,131,125,123,115,115)28.822.936.433.638.433.333.936.5
Redness-Mod (n=131,129,128,128,124,119,113,114)0.01.63.11.65.63.410.612.3
Redness-Severe(n=131,129,128,128,124,119,112,113)0.00.00.00.00.00.00.00.9
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)

Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after each dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)
percentage of participants13vPnC Manufacturing Dose 113vPnC Pilot Dose 113vPnC Manufacturing Dose 213vPnC Pilot Dose 213vPnC Manufacturing Dose 313vPnC Pilot Dose 3
Fever ≥38°C but ≤39°C (n=132,130,129,130,124,121)18.219.216.320.011.317.4
Fever >39°C but ≤40°C (n=131,129,128,128,124,119)0.80.80.81.60.03.4
Fever >40°C (n=131,129,128,128,124,119)0.00.00.00.00.00.0
Decreased appetite (n=133,129,129,128,125,121)20.324.014.715.616.819.0
Irritability (n=134,131,130,131,127,123)50.051.953.849.641.737.4
Increased sleep (n=132,129,128,129124,121)41.739.525.029.520.230.6
Decreased sleep (n=132,130,129,129,124,123)27.332.324.020.918.519.5
Meds to treat sx (n=132,130,128,128,124,123)12.917.713.314.18.914.6
Meds to prevent sx (n=132,130,128,129124,121)12.99.211.710.110.58.3
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)

Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
During the 4-day period after toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)
percentage of participants13vPnC Manufacturing13vPnC Pilot
Fever ≥38°C but ≤39°C (n=114,114)14.013.2
Fever >39°C but ≤40°C (n=112,113)0.90.9
Fever >40°C (n=112,113)0.00.0
Decreased appetite (n=115,117)20.923.1
Irritability (n=119,123)40.344.7
Increased sleep (n=114,119)18.416.8
Decreased sleep (n=116,117)13.813.7
Medication to treat symptoms (n=113,115)17.717.4
Medication to prevent symptoms (n=114,114)12.312.3
PrimaryGeometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series

Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
One month after 3-dose infant series (5 months of age)
Reported as:
Geometric mean · μg/mL
Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series
μg/mL13vPnC Manufacturing13vPnC Pilot
Common Serotypes-Serotype 42.09 (1.81 to 2.40)1.55 (1.34 to 1.79)
Common Serotypes - Serotype 6B0.80 (0.65 to 0.98)0.83 (0.66 to 1.06)
Common Serotypes - Serotype 9V1.28 (1.13 to 1.43)1.21 (1.08 to 1.37)
Common Serotypes - Serotype 142.15 (1.77 to 2.61)2.30 (1.91 to 2.77)
Common Serotypes - Serotype 18C1.60 (1.38 to 1.87)1.51 (1.31 to 1.75)
Common Serotypes - Serotype 19F1.60 (1.40 to 1.83)1.64 (1.44 to 1.86)
Common Serotypes - Serotype 23F0.82 (0.69 to 0.98)0.92 (0.77 to 1.10)
Additional Serotypes - Serotype 11.42 (1.21 to 1.66)1.29 (1.10 to 1.51)
Additional Serotypes - Serotype 31.20 (1.05 to 1.38)1.21 (1.06 to 1.37)
Additional Serotypes - Serotype 50.96 (0.84 to 1.09)1.00 (0.87 to 1.16)
Additional Serotypes - Serotype 6A0.87 (0.74 to 1.03)1.05 (0.89 to 1.25)
Additional Serotypes - Serotype 7F2.00 (1.77 to 2.25)2.14 (1.89 to 2.42)
Additional Serotypes - Serotype 19A2.19 (1.91 to 2.50)2.31 (2.05 to 2.61)
Statistical analysis
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 1.35 · 95% CI 1.10 to 1.65
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.96 · 95% CI 0.70 to 1.31
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 1.05 · 95% CI 0.89 to 1.24
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.93 · 95% CI 0.71 to 1.22
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 1.06 · 95% CI 0.86 to 1.30
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.98 · 95% CI 0.81 to 1.17
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.90 · 95% CI 0.70 to 1.15
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 1.10 · 95% CI 0.88 to 1.37
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 1.00 · 95% CI 0.83 to 1.20
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.95 · 95% CI 0.79 to 1.16
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.83 · 95% CI 0.66 to 1.05
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.93 · 95% CI 0.79 to 1.11
  • 13vPnC Manufacturing vs 13vPnC Pilot · Ratio: 0.95 · 95% CI 0.79 to 1.13

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Manufacturing Infant Series—4/134 (3%)70/134 (52.2%)
13vPnC Pilot Infant Series—2/134 (1.5%)68/134 (50.7%)
13vPnC Manufacturing Post-Infant Series—10/134 (7.5%)3/134 (2.2%)
13vPnC Pilot Post-Infant Series—11/134 (8.2%)7/134 (5.2%)
13vPnC Manufacturing Toddler Series—0/131 (0%)48/131 (36.6%)
13vPnC Pilot Toddler Series—1/131 (0.8%)55/131 (42%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
Event13vPnC Manufacturing Infant Series13vPnC Pilot Infant Series13vPnC Manufacturing Post-Infant Series13vPnC Pilot Post-Infant Series13vPnC Manufacturing Toddler Series13vPnC Pilot Toddler Series
GastroenteritisInfections and infestations0/1340/1343/1344/1340/1311/131
PneumoniaInfections and infestations1/1340/1342/1343/1340/1310/131
AsthmaRespiratory, thoracic and mediastinal disorders0/1340/1342/1340/1340/1310/131
BronchitisInfections and infestations1/1340/1341/1342/1340/1310/131
DiarrhoeaGastrointestinal disorders0/1341/1342/1341/1340/1310/131
LaryngitisInfections and infestations1/1340/1342/1341/1340/1310/131
Upper respiratory tract infectionInfections and infestations0/1341/1341/1342/1340/1310/131
BronchopneumoniaInfections and infestations0/1340/1341/1340/1340/1310/131
BronchospasmRespiratory, thoracic and mediastinal disorders1/1340/1340/1340/1340/1310/131
ConjunctivitisEye disorders0/1340/1340/1341/1340/1310/131
Most frequent other events
Showing 10 of 115
Most frequent other events
Event13vPnC Manufacturing Infant Series13vPnC Pilot Infant Series13vPnC Manufacturing Post-Infant Series13vPnC Pilot Post-Infant Series13vPnC Manufacturing Toddler Series13vPnC Pilot Toddler Series
IrritabilityGeneral disorders70/13065/1310/1340/1340/1310/131
IrritabilityGeneral disorders67/13468/1310/1340/13448/11955/123
Erythema (Any)Skin and subcutaneous tissue disorders38/13232/1310/1340/13443/11549/116
IrritabilityGeneral disorders53/12746/1230/1340/1340/1310/131
Increased sleepGeneral disorders55/13251/1290/1340/13421/11420/119
Erythema (Any)Skin and subcutaneous tissue disorders50/12542/1230/1340/1340/1310/131
Erythema (Mild)Skin and subcutaneous tissue disorders48/12541/1230/1340/1340/1310/131
Erythema (Any)Skin and subcutaneous tissue disorders48/12944/1310/1340/1340/1310/131
Erythema (Mild)Skin and subcutaneous tissue disorders38/13230/1310/1340/13439/11542/115
Erythema (Mild)Skin and subcutaneous tissue disorders47/12944/1310/1340/1340/1310/131

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC Manufacturing13vPnC PilotTotal
Mean2.1 ± 0.62.1 ± 0.52.1 ± 0.5
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC Manufacturing13vPnC PilotTotal
Female6567132
Male7067137
08

Study locations

9 sites
  • Torun, Bydgoszcz 87-100, Poland
  • Siemianowice Slaskie, Krakow 41-103, Poland
  • Lubartowie, Lublin 21-100, Poland
  • Krakow, 30-663, Poland
  • Krakow, 31-442, Poland
  • Lodz, 91-347, Poland
  • Lodz, 93-338, Poland
  • Lublin, 20-044, Poland
  • Warszawa, 01-184, Poland
09

References and documents

Publications

  • Gadzinowski J, Albrecht P, Hasiec B, Konior R, Dziduch J, Witor A, Mellelieu T, Tansey SP, Jones T, Sarkozy D, Emini EA, Gruber WC, Scott DA. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. Vaccine. 2011 Apr 5;29(16):2947-55. doi: 10.1016/j.vaccine.2011.02.002. Epub 2011 Feb 16. PubMed 21335032 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 3 years 11 months after primary completion. A results delay was requested in Feb 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2007
First posted
Apr 24, 2007
Start
Jun 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results delay requested
Feb 26, 2009
Results first posted
Aug 15, 2012
Last update
Aug 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00464945
Responsible party
Sponsor
First posted
Apr 24, 2007
Start date
Jun 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Aug 15, 2012
Last update
Aug 15, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
Trial Manager
principal investigator · For Poland, WPWZMED@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion